FDA thwarts Agenus' ac­cel­er­at­ed ap­proval plans for CT­LA-4/PD-1 com­bo in 'dis­ap­point­ing' move

Agenus is shelv­ing im­me­di­ate plans for a con­fir­ma­to­ry Phase 3 study for its lead im­munother­a­py pro­gram af­ter the FDA “dis­cour­aged” it from fil­ing for ac­cel­er­at­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER